80 results
20-F/A
2023 FY
CSCI
COSCIENS Biopharma Inc.
16 Jul 24
Annual report (foreign) (amended)
6:22pm
employees. The use of this information is critical to our operations and innovation, including the development of our products, as well as management … authorization to the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation, or if its authorization
6-K
CSCI
COSCIENS Biopharma Inc.
14 May 24
Consolidated Financial Statements
6:44pm
in connection with clinical activities and employees. The use of this information is critical to the Combined Company’s operations and innovation, including … related to products derived from the technologies. Commercial success depends on many factors including the degree of innovation of the products
6-K
EX-99.2
CSCI
COSCIENS Biopharma Inc.
14 May 24
Consolidated Financial Statements
6:44pm
, and spray chamber unit for the Company’s PGX Technology with the aim to boost the innovation capacity of the technology towards pharmaceutical … depends on many factors including the degree of innovation of the products developed, access to funding for scale-up opportunities, uncertainties
6-K
EX-99.1
CSCI
COSCIENS Biopharma Inc.
14 May 24
Consolidated Financial Statements
6:44pm
to boost the innovation capacity of the technology towards pharmaceutical applications. During the year ended December 31, 2021, the Company recognized
F-1/A
CSCI
COSCIENS Biopharma Inc.
29 Apr 24
Registration statement (foreign) (amended)
6:02pm
, both in connection with clinical activities and employees. The use of this information is critical to the Combined Company’s operations and innovation … market conditions in the biopharmaceutical sector. The Combined Company plans to prioritize agility, innovation, and adaptability to navigate
F-1
vnymxg427501
15 Feb 24
Registration statement (foreign)
4:54pm
6-K
EX-99.1
aclck7pbfft
9 Apr 21
Annual Meeting of Shareholders
5:23pm
40-F
EX-99.1
n09wxgao8swb
25 Mar 21
Annual report (Canada)
12:00am
20-F/A
EX-2.2
mvujmjcvh7ll4le27ms
18 Jun 20
Annual report (foreign) (amended)
4:10pm
6-K
EX-99.1
p4q1tln
21 Apr 20
Annual Meeting of Shareholders
12:00am
424B5
7k69vufj
21 Feb 20
Prospectus supplement for primary offering
9:33am
6-K
EX-99.1
r2v80bpu 8sv
16 Dec 19
Aeterna Zentaris Announces 2020 Director Changes
9:00am
424B5
okb41evdd 9a
20 Sep 19
Prospectus supplement for primary offering
4:37pm
6-K
EX-3
tbthg
1 Apr 19
Current report (foreign)
12:00am
6-K
EX-99.1
7kcnt
8 May 18
Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
4:19pm
6-K
EX-99.1
060zlqx jabekx58
9 Apr 18
Annual and Special Meeting of Shareholders
12:00am